30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: DePuy Synthes/Johnson & Johnson

$2,344MM, +2.9% (U.S. $1,272MM, +3.2%, ex-U.S. $1,072MM, +2.4%)

  • Hips +4% (U.S. +4%, ex-U.S. +4%)
  • Knees +5% (U.S. +5%, ex-U.S. +6%)
  • Trauma +3%

 

Nine months through 3Q14:

$7,234MM, +3.0% (U.S. $3,858MM, +2.4%; ex-U.S. $3,376MM, +3.5%)
(JNJ does not state segment growth for 9 months)

 

  • “Seeing the benefit of having a broader offering in orthopedics”
  • Hip/knee growth supported by primary stem platform, ATTUNE knee; both offset by price pressure
  • U.S. price mix for hips -5%, knees -0.6%, spine -4%, trauma +2%
  • Estimates U.S. market for hips +3%, knees +4%
  • Trauma up on market growth and new products
  • Sports Medicine driven by MONOVISC launch + strong continued growth for ORTHOVISC
  • Continued pricing pressure across all major categories